CRE­LUX GmbH

CRE­LUX spe­cial­izes in tail­or made pro­tein and pro­tein crys­tal­lo­graphy drug dis­cov­ery ser­vices. The com­pany is a pro­fes­sion­al and ded­ic­ated ser­vice pro­vider for the glob­al pharma, biotech and dia­gnostics industry. CRE­LUX is inde­pend­ent and privately owned with no ven­ture cap­it­al or oth­er extern­al invest­ment. The com­pany is solely com­mit­ted to long-term devel­op­ment and growth with all profit being re-inves­ted into the busi­ness. CRE­LUX is a cli­ent focused com­pany with a port­fo­lio of premi­um drug dis­cov­ery ser­vices based on our top level pro­tein expert­ise. In our PRIME PRO­TEIN pro­grams we are advan­cing innov­a­tions in pro­tein expres­sion to pro­mote the avail­ab­il­ity of high qual­ity pro­teins. Our XPRESS port­fo­lio of read­ily avail­able crys­tal­lo­graph­ic tar­gets grants turn-around times for com­plex struc­tures of only a few weeks. XPERT crys­tal­lo­graphy ser­vices from concept to high res­ol­u­tion com­plex struc­ture are provided under indi­vidu­al agree­ments fol­low­ing our customer’s needs. Based on our unique screen­ing tech­no­logy INTRACT we are provid­ing com­pound and frag­ment screen­ing. Finally, our I2C (idea to can­did­ate) pro­gram offers com­pre­hens­ive tar­get to hit and concept to early devel­op­ment can­did­ate fee-for-ser­vice projects.